Myers Laura C, Bosch Nicholas A, Soltesz Lauren, Daly Kathleen A, Campbell Cynthia I, Schwager Emma, Salvati Emmanuele, Stevens Jennifer P, Wunsch Hannah, Rucci Justin M, Jafarzadeh S Reza, Liu Vincent X, Walkey Allan J
Division of Research, Kaiser Permanente Northern California, Oakland, CA.
The Permanente Medical Group, Kaiser Permanente Northern California, Oakland, CA.
Crit Care Explor. 2024 Jul 17;6(7):e1123. doi: 10.1097/CCE.0000000000001123. eCollection 2024 Jul 1.
The opioid crisis is impacting people across the country and deserves attention to be able to curb the rise in opioid-related deaths.
To evaluate practice patterns in opioid infusion administration and dosing for patients with acute respiratory failure receiving invasive mechanical ventilation.
Retrospective cohort study.
Patients from 21 hospitals in Kaiser Permanente Northern California and 96 hospitals in Philips electronic ICU Research Institute.
We assessed whether patients received opioid infusion and the dose of said opioid infusion.
We identified patients with a diagnosis of acute respiratory failure who were initiated on invasive mechanical ventilation. From each patient, we determined if opioid infusions were administered and, among those who received an opioid infusion, the median daily dose of fentanyl infusion. We used hierarchical regression models to quantify variation in opioid infusion use and the median daily dose of fentanyl equivalents across hospitals. We included 13,140 patients in the KPNC cohort and 52,033 patients in the eRI cohort. A total of 7,023 (53.4%) and 16,311 (31.1%) patients received an opioid infusion in the first 21 days of mechanical ventilation in the KPNC and eRI cohorts, respectively. After accounting for patient- and hospital-level fixed effects, the hospital that a patient was admitted to explained 7% (95% CI, 3-11%) and 39% (95% CI, 28-49%) of the variation in opioid infusion use in the KPNC and eRI cohorts, respectively. Among patients who received an opioid infusion, the median daily fentanyl equivalent dose was 692 µg (interquartile range [IQR], 129-1341 µg) in the KPNC cohort and 200 µg (IQR, 0-1050 µg) in the eRI cohort. Hospital explained 4% (95% CI, 1-7%) and 20% (95% CI, 15-26%) of the variation in median daily fentanyl equivalent dose in the KPNC and eRI cohorts, respectively.
In the context of efforts to limit healthcare-associated opioid exposure, our findings highlight the considerable opioid exposure that accompanies mechanical ventilation and suggest potential under and over-treatment with analgesia. Our results facilitate benchmarking of hospitals' analgesia practices against risk-adjusted averages and can be used to inform usual care control arms of analgesia and sedation clinical trials.
阿片类药物危机正在影响全国人民,值得关注以遏制与阿片类药物相关的死亡人数上升。
评估接受有创机械通气的急性呼吸衰竭患者阿片类药物输注给药和剂量的实践模式。
回顾性队列研究。
来自北加利福尼亚凯撒医疗集团21家医院以及飞利浦电子重症监护研究机构96家医院的患者。
我们评估患者是否接受阿片类药物输注以及所述阿片类药物输注的剂量。
我们确定了诊断为急性呼吸衰竭且开始接受有创机械通气的患者。对于每位患者,我们确定是否给予了阿片类药物输注,以及在接受阿片类药物输注的患者中,芬太尼输注的每日中位剂量。我们使用分层回归模型来量化各医院在阿片类药物输注使用情况以及芬太尼等效物每日中位剂量方面的差异。凯撒医疗集团队列纳入了13140名患者,电子重症监护研究机构队列纳入了52033名患者。在凯撒医疗集团队列和电子重症监护研究机构队列中,分别有7023名(53.4%)和16311名(31.1%)患者在机械通气的前21天接受了阿片类药物输注。在考虑患者和医院层面的固定效应后,患者所入住的医院分别解释了凯撒医疗集团队列和电子重症监护研究机构队列中阿片类药物输注使用差异的7%(95%置信区间,3%-11%)和39%(95%置信区间,28%-49%)。在接受阿片类药物输注的患者中,凯撒医疗集团队列中芬太尼等效物的每日中位剂量为692微克(四分位间距[IQR],129 - 1341微克),电子重症监护研究机构队列中为200微克(IQR,0 - 1050微克)。医院分别解释了凯撒医疗集团队列和电子重症监护研究机构队列中芬太尼等效物每日中位剂量差异的4%(95%置信区间,1%-7%)和20%(95%置信区间,15%-26%)。
在努力限制医疗相关阿片类药物暴露的背景下,我们的研究结果突出了机械通气伴随的大量阿片类药物暴露,并提示镇痛可能存在治疗不足和过度治疗的情况。我们的结果有助于将医院的镇痛实践与风险调整后的平均值进行对比,并可用于为镇痛和镇静临床试验的常规护理对照组提供参考。